Stock Alert: Vaccinex Jumps 16%; Announces Deal With Merck

(RTTNews) - Shares of clinical-stage biotechnology company, Vaccinex, Inc. (VCNX) are rising more than 16% Thursday morning after the company announced that it has entered into a clinical collaboration agreement with Merck.

The partnership is to evaluate the combination of Vaccinex's investigational SEMA4D inhibitor, pepinemab, and Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

VCNX is currently trading at $6.18. It has been trading in the range of $3.22- $12.23 in the last 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More